- Dianthus Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Magenta Therapeutics Inc Definitive Merger Agreement with Dianthus Therapeutics Inc - M&A Call TranscriptMay 03, 2023
- Magenta Therapeutics Inc Update on MGTA-117 - Corporate Call TranscriptDec 13, 2022
- Magenta Therapeutics Inc at Credit Suisse Healthcare Conference TranscriptNov 08, 2022
- Magenta Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 13, 2022
- Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Magenta Therapeutics Inc MGTA-145 MM Phase 2 Clinical Trial Results Call TranscriptMay 12, 2021
- Magenta Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- Magenta Therapeutics, Inc. - Special Call TranscriptMay 07, 2020
- Magenta Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Magenta Therapeutics Inc ASH 2019 TranscriptDec 08, 2019
- Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 11, 2019
Magenta Therapeutics Inc MGTA-145 MM Phase 2 Clinical Trial Results Call Transcript
Good day, and thank you for standing by. Welcome to the Magenta Therapeutics Conference Call. (Operator Instructions)
I would now like to hand the conference over to your first speaker today, Jim Haney, Senior Director, Investor Relations. Thank you. Please go ahead.
Thank you, Paul, and good afternoon, everyone. Thank you for joining us today for a review of the preliminary data from the MGTA-145 in combination with plerixafor Phase II study in patients with multiple myeloma, disclosed in the abstract posted this morning for the European Hematology Association Congress to be held in June. We issued a press release earlier this morning on the preliminary data, and that press release can be found on the Investors and Media section of our website.
With me on the call today are Dr. Jason Gardner, Magenta Therapeutics President, CEO and Co-Founder; Dr. John Davis, Chief Medical Officer and Head of Research and Development; Steve Mahoney, Chief Financial and Operating Officer; Dr. David
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)